Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2000-05-23
2001-07-17
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S396000
Reexamination Certificate
active
06262057
ABSTRACT:
The present invention relates to new pseudopolymorphic crystalline forms of 2-[2-[4-[bis(4-fluorophenyl)methyl]-1-piperazinyl]ethoxy]acetic acid dihydrochloride, to processes for their preparation and to pharmaceutical compositions containing them.
2-[2-[4-[Bis(4-fluorophenyl)methyl]-1-piperazinyl]ethoxy]acetic acid, also known and hereinafter referred to as efletirizine (INN: International Non-proprietary Name), is the compound of the following formula:
Efletirizine is encompassed within general formula I of European patent No. 58146 in the name of the applicant, which relates to substituted benzhydrylpiperazine derivatives.
Like 2-[2-[4-1(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic acid, also known and hereinafter referred to as cetirizine (INN), efletirizine has been found to possess excellent antihistaminic properties. It belongs to the pharmacological class of second generation histamine H
1
-receptor antagonists and shows in vitro high affinity and selectivity for H
1
-receptors. Like cetirizine, it is useful as an antiallergic, antihistaminic, bronchodilator and antispasmodic agent. Recent clinical studies have shown the utility of efletirizine when administered in the form of a nasal spray for the treatment of allergic rhinitis and rhino-conjunctivitis (J. -F. Dessanges et al., Allergy and Clin. Immunol. News (1994), Suppl. n°2, abstract 1864; C. De Vos et al., Allergy and Clin. Immunol. News (1994), Suppl. n°2, abstract 428).
Another recent clinical pharmacology study (to be published) has shown that efletirizine gives unexpectedly good results In the treatment of urticaria, atopic dermatitis and prurit.
Due to increasing therapeutic interest for efletirizine, we have set out to prepare pharmaceutical compositions containing efletirizine.
Efletirizine is an amorphous solid. However, it is highly desirable to dispose of a product with reproducible characteristics, which always performs in the same way during formulation. in particular in order to comply with regulatory requirements. For these reasons, we attempted to prepare crystalline forms of efletirizine. Although efletirizine has been studied for its therapeutic utility, no attention has yet been given to such crystalline forms.
REFERENCES:
patent: 4525358 (1985-06-01), Baltes et al.
patent: 5419898 (1995-05-01), Ikejiri et al.
patent: 5968551 (1999-10-01), Oshlack et al.
patent: 0 058 146 (1982-08-01), None
patent: 0 801 064 (1997-10-01), None
patent: 2 351 964 (1977-12-01), None
patent: 1 174 819 (1969-12-01), None
patent: 1 561 286 (1980-02-01), None
patent: 2 225 320 (1990-05-01), None
patent: 2 225 321 (1990-05-01), None
patent: 135643 (1997-04-01), None
patent: 97/37982 (1997-10-01), None
patent: 97/2973 (1998-01-01), None
Berwaer Monique
Bodson Guy
Deleers Michel
Dogimont Charles
Fanara Domenico
Bernhardt Emily
UCB S.A.
Wenderoth Lind & Ponack LLP
LandOfFree
Pseudopolymorphic forms of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pseudopolymorphic forms of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pseudopolymorphic forms of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2521696